United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock

Key Points

• CEO Martine Rothblatt sold 9,500 shares of United Therapeutics at an average price of $518.74, generating approximately $4.93 million. The transaction reduced her direct ownership by 2.84%, though she still holds 324,443 shares.
• Second-quarter earnings were stronger than expected, with EPS of $7.27 versus the $6.86 consensus estimate. However, revenue of $783.3 million missed estimates and declined 1.9% year over year.
• Analyst sentiment remains generally positive, with a consensus “Moderate Buy” rating and an average price target of $646. The company’s pipeline, including ralinepag and Tyvaso-related programs, is viewed as a potential longer-term growth driver.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $518.74, for a total value of $4,928,030.00. Following the completion of the sale, the chief executive officer owned 324,443 shares in the company, valued at approximately $168,301,561.82. The trade was a 2.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

United Therapeutics Stock Performance

United Therapeutics stock traded up $13.93 during mid-day trading on Thursday, hitting $532.94. The company's stock had a trading volume of 992,945 shares, compared to its average volume of 490,031. The company has a 50 day moving average of $540.37 and a 200-day moving average of $533.71. The stock has a market cap of $22.62 billion, a PE ratio of 19.67, a P/E/G ratio of 1.73 and a beta of 0.59. United Therapeutics Corporation has a one year low of $292.34 and a one year high of $609.35.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping the consensus estimate of $6.86 by $0.41. The business had revenue of $783.30 million during the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business's revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period last year, the company earned $6.41 earnings per share. On average, equities research analysts forecast that United Therapeutics Corporation will post 26.65 EPS for the current fiscal year.

Institutional Trading of United Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Arjuna Capital boosted its holdings in shares of United Therapeutics by 2.8% in the first quarter. Arjuna Capital now owns 662 shares of the biotechnology company's stock valued at $393,000 after acquiring an additional 18 shares during the period. Sage Rhino Capital LLC increased its holdings in shares of United Therapeutics by 5.1% in the 1st quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company's stock valued at $281,000 after acquiring an additional 23 shares during the period. Bryn Mawr Trust Advisors LLC raised its position in United Therapeutics by 5.4% in the 1st quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company's stock valued at $276,000 after purchasing an additional 24 shares during the last quarter. Meeder Advisory Services Inc. boosted its stake in United Therapeutics by 4.1% during the 1st quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company's stock worth $392,000 after purchasing an additional 26 shares during the period. Finally, Independent Advisor Alliance boosted its stake in United Therapeutics by 3.3% during the 4th quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company's stock worth $406,000 after purchasing an additional 27 shares during the period. Institutional investors own 94.08% of the company's stock.

Key United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Analyst support remained strong. H.C. Wainwright reiterated its Buy rating and maintained a $660 price target, citing United Therapeutics’ diversified pipeline as a counterbalance to near-term headwinds. Buy Rating Reiterated on United Therapeutics as Diversified Pipeline Offsets Near-Term Headwinds
• Positive Sentiment: Second-quarter EPS beat expectations. United Therapeutics reported earnings of $7.27 per share, above the roughly $6.82–$6.86 analyst consensus and up from $6.41 a year earlier. The company also posted a 40.62% net margin, supporting the stock’s valuation. United Therapeutics Q2 Earnings Surpass Estimates
• Positive Sentiment: Pipeline developments improved the longer-term outlook. Management highlighted regulatory submissions and continued progress for ralinepag and Tyvaso-related programs. Analysts view these products as potential future growth drivers that could diversify the company beyond its existing pulmonary arterial hypertension therapies. United Therapeutics Corporation Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Royal Bank of Canada lowered its price target from $704 to $677 but retained an Outperform rating, still implying substantial potential upside from recent trading levels. The reduction signals more cautious near-term assumptions rather than a change to the overall bullish view. Benzinga
• Negative Sentiment: Revenue missed estimates and declined year over year. Second-quarter revenue was $783.3 million, below the $804.65 million consensus and down about 2% from the prior year. Competitive pressure and concerns surrounding Tyvaso are the primary near-term operating headwinds. United Therapeutics Q2 Earnings Beat Estimates, Revenues Miss Mark
• Negative Sentiment: CEO Martine Rothblatt sold approximately $4.9 million of stock. The sale reduced her direct holdings by 2.84%, potentially weighing modestly on sentiment, although she continues to own a substantial position. United Therapeutics CEO Stock Sale Filing

Analyst Ratings Changes

A number of equities analysts have commented on UTHR shares. Weiss Ratings downgraded shares of United Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a research note on Friday, July 31st. Wells Fargo & Company raised shares of United Therapeutics from an "equal weight" rating to an "overweight" rating and lifted their price target for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. Raymond James Financial assumed coverage on United Therapeutics in a report on Friday, April 10th. They issued an "outperform" rating and a $700.00 price target for the company. TD Cowen restated a "buy" rating on shares of United Therapeutics in a report on Thursday, May 21st. Finally, JPMorgan Chase & Co. lifted their target price on United Therapeutics from $685.00 to $687.00 and gave the company an "overweight" rating in a research report on Thursday, July 23rd. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $646.00.

United Therapeutics Company Profile

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source